Watch Dogs: Legion – Legacy – Announcement Trailer – Ubisoft Russia

  1. Watch Dogs: Legion – Legacy – Announcement TrailerUbisoft Russia
  2. Story DLC for Watch Dogs: Legion with heroes from previous games will be released on July 63DNews
  3. Watch Dogs Legion: First Trailer for Bloodline – “Legacy” ReleasedCannabis
  4. Aiden Pearce almost made it to Watch Dogs: LegionKG-Portal
  5. Aiden Pearce & Wrench Return July 6th – New Watch Dogs: Legion – Bloodline TrailerPlayGround.ru
  6. View in the Google News app

.

Mbappé: ” He told me that I should come and play for Bayern Munich; it’s one of the best clubs in the world ” – Ten

The president of the PSG He was forceful last weekend when talking about the future of his star player, Kylian Mbappé. Nasser Al-Khelaifi slammed the door to ensure that the Frenchman will not leave the club in this market and that he will not leave free when his contract ends (in 2022), after the indications that link him to the Real Madrid.

Al-Khelaifi closes the exit doors to Mbappé at PSG

The president wanted to settle rumors about the forward’s future, but he once again refused to make a verbal commitment to the Parisian club when asked about it.

Mbappé reacted to the statements of Nasser throwing an ambiguous message. “In football, you never know what is going to happen,” he said to SportBild, adding that “I am currently very happy.”

The German newspaper also asked him about the Bayern Munich, a club admired by the player himself and that was eliminated by the PSG in the Champions League last season.

“Lucas Hernández told me that I should come to Munich to play for Bayern,” he said. Mbappé. ” Bayern are one of the five best clubs in the world. One can only congratulate them on how they manage to maintain quality in the squad every year. They just know what they are doing. ”

This is how PSG signed Mbappé and prevented him from going to Real Madrid

Now Boateng and Alaba have left, but Upamecano, who is an excellent defender, came in. They have a clear concept that makes them a great club. ”

And yes, you are always a favorite for any title. So I will always have to beat Bayern in the future if I want to win a trophy. ”

.

Dexcom looks to the future of continuous blood glucose monitoring | 06/04/21

DexCom, Inc. (Nasdaq: DXCM), the world leader in continuous, real-time blood glucose monitoring for people with diabetes, announced today during the 14th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) the Publication and presentation of two new studies announced.

These two studies, which focus on the clinical outcomes of the use of continuous glucose monitoring (CGM) in broader and more diverse patient populations, as well as new data from DexCom’s next-generation CGM device, represent a pivotal moment in the Innovation in Diabetes Care at one of the world’s leading industry conferences.

MOBILE-Studie

The MOBILE study, which is part of the Journal of the American Medical Association published is the first of its kind to find that people with type 2 diabetes who use basal or background insulin have benefited from using CGM. With the release of the MOBILE data, Dexcom has now demonstrated significant results from its CGM technology in randomized controlled trials across the entire spectrum of insulin use in people with diabetes.

Key clinical benefits of using Dexcom’s CGM in this patient population include:

  • More time in the measuring range
  • Significant A1c reduction
  • More patients achieve A1c goals
  • A sharp decrease in hyperglycemia

The randomized clinical trial, led by the International Diabetes Center of the HealthPartners Institute and coordinated by the Jaeb Center for Health Research in Tampa, Florida, reaffirms Dexcom’s belief in the power of CGM for all people with diabetes, regardless of type .

“The clinical benefits of Dexcom’s CGM have been seen in patients from all demographics, regardless of age, education, numeracy, or socioeconomic status,” said Dr. med. David Price, Dexcom Medical Affairs Director. “The design of the MOBILE study also reinforces our ability to meet the needs of the different communities we serve.”

Results of the MOBILE study

  • On average, the group of patients using Dexcom’s CGM spent 3.8 hours more per day in the optimal blood sugar range (70–180 mg / dl), 3.6 hours less per day in the very high blood sugar range (> 250 mg / dl) dl) and they experienced a reduction in the hypoglycaemia measured with CGM in the CGM group compared to the group with glucose measurement on the fingertip.
  • 63% of patients who used CGM to adjust therapy had an HbA1c level of less than 8%, compared to only 39% of patients who had fingertip glucose testing.
  • The group who used CGM to control therapy and lifestyle adjustments also had significantly lower HbA1c values ​​(9.1 to 8.0%) than the group of patients who used traditional glucose measurement with a drop of blood from the fingertip (9 , 0 to 8.4%); this was an adjusted difference in the mean change in HbA1c of -0.4% (95% CI: -0.8 to -0.1%; p = 0.02).
  • Therapy compliance and satisfaction were also high in the CGM group.

Design of the MOBILE study

  • Eight-month long study with 175 ethnically and socio-economically different adults (including> 50% people of color) at 15 test centers.
  • Type 2 diabetics aged 30 or over who were being looked after by a family doctor and trying to control their diabetes with basal or background insulin but were not using faster-acting insulin with meals.
  • Two-thirds of the study participants were designated to use the Dexcom CGM and were encouraged to use the Dexcom software applications CLARITY, Share and Follow; the remaining third of the study participants were assigned the use of a conventional blood glucose meter.

Data from Dexcom G7

In addition, Dexcom presented new data on its compatible next-generation CGM device, the Dexcom G7, from clinical studies supporting the company’s efforts to obtain CE Marking, as well as from work prior to pivot studies in the United States. The data reflect the latest G7 technology and prove the consistent performance of the sensor across the spectrum of glucose readings and the length of time it was worn.

G7 results (approx. 360 sensor sessions)

  • A total mean absolute relative difference (MARD) of 8.7%
  • 93.8 percent% 20/20
  • 99% of the sensor readings were clinically accurate and safe for treatment decisions

Expected Features and Benefits of the Dexcom G7

  • 60% smaller carrying system than G6
  • Smaller all-in-one sensor applicator and transmitter
  • 30-minute warm-up phase
  • Compatibility with insulin delivery devices
  • Maintaining the great customer experience
  • Still best in class accuracy

“Initial clinical data has reinforced our belief that the Dexcom G7 builds on the high level of precision our G6-CGM has achieved,” said Jake Leach, executive vice president and chief technology officer, Dexcom. “The G7 is a completely redesigned CGM device; our users will get a whole host of new features that we believe will enhance the customer experience that has become synonymous with Dexcom.”

In addition to the MOBILE study and the G7 data, many other presentations and posters from ATTD underpinned the advantages of the CGM from Dexcom for intensive insulin management as well as use in inpatient facilities and during pregnancy.

Über DexCom, Inc.

Headquartered in San Diego, California, DexCom, Inc. is dedicated to helping people better manage their diabetes symptoms through the development and marketing of continuous glucose monitoring (CGM) products and tools for adult and pediatric patients. Thanks to the exceptional performance, patient comfort and lifestyle flexibility that are at the heart of DexCom technology, users have consistently rated DexCom the highest in terms of customer satisfaction and loyalty. More information is available at www.dexcom.com.

The source language in which the original text is published is the official and authorized version. Translations will be included for a better understanding. Only the language version that was originally published is legally valid. You should therefore compare the translations with the original language version of the publication.

.

Dexcom looks to the future of continuous blood glucose monitoring | 06/04/21

DexCom, Inc. (Nasdaq: DXCM), the world leader in continuous, real-time blood glucose monitoring for people with diabetes, announced today during the 14th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) the Publication and presentation of two new studies announced.

These two studies, which focus on the clinical outcomes of the use of continuous glucose monitoring (CGM) in broader and more diverse patient populations, as well as new data from DexCom’s next-generation CGM device, represent a pivotal moment in the Innovation in Diabetes Care at one of the world’s leading industry conferences.

MOBILE-Studie

The MOBILE study, which is part of the Journal of the American Medical Association published is the first of its kind to find that people with type 2 diabetes who use basal or background insulin have benefited from using CGM. With the release of the MOBILE data, Dexcom has now demonstrated significant results from its CGM technology in randomized controlled trials across the entire spectrum of insulin use in people with diabetes.

Key clinical benefits of using Dexcom’s CGM in this patient population include:

  • More time in the measuring range
  • Significant A1c reduction
  • More patients achieve A1c goals
  • A sharp decrease in hyperglycemia

The randomized clinical trial, led by the International Diabetes Center of the HealthPartners Institute and coordinated by the Jaeb Center for Health Research in Tampa, Florida, reaffirms Dexcom’s belief in the power of CGM for all people with diabetes, regardless of type .

“The clinical benefits of Dexcom’s CGM have been seen in patients from all demographics, regardless of age, education, numeracy, or socioeconomic status,” said Dr. med. David Price, Dexcom Medical Affairs Director. “The design of the MOBILE study also reinforces our ability to meet the needs of the different communities we serve.”

Results of the MOBILE study

  • On average, the group of patients using Dexcom’s CGM spent 3.8 hours more per day in the optimal blood sugar range (70–180 mg / dl), 3.6 hours less per day in the very high blood sugar range (> 250 mg / dl) dl) and they experienced a reduction in the hypoglycaemia measured with CGM in the CGM group compared to the group with glucose measurement on the fingertip.
  • 63% of patients who used CGM to adjust therapy had an HbA1c level of less than 8%, compared to only 39% of patients who had fingertip glucose testing.
  • The group who used CGM to control therapy and lifestyle adjustments also had significantly lower HbA1c values ​​(9.1 to 8.0%) than the group of patients who used traditional glucose measurement with a drop of blood from the fingertip (9 , 0 to 8.4%); this was an adjusted difference in the mean change in HbA1c of -0.4% (95% CI: -0.8 to -0.1%; p = 0.02).
  • Therapy compliance and satisfaction were also high in the CGM group.

Design of the MOBILE study

  • Eight-month long study with 175 ethnically and socio-economically different adults (including> 50% people of color) at 15 test centers.
  • Type 2 diabetics aged 30 or over who were being looked after by a family doctor and trying to control their diabetes with basal or background insulin but were not using faster-acting insulin with meals.
  • Two-thirds of the study participants were designated to use the Dexcom CGM and were encouraged to use the Dexcom software applications CLARITY, Share and Follow; the remaining third of the study participants were assigned the use of a conventional blood glucose meter.

Data from Dexcom G7

In addition, Dexcom presented new data on its compatible next-generation CGM device, the Dexcom G7, from clinical studies supporting the company’s efforts to obtain CE Marking, as well as from work prior to pivot studies in the United States. The data reflect the latest G7 technology and prove the consistent performance of the sensor across the spectrum of glucose readings and the length of time it was worn.

G7 results (approx. 360 sensor sessions)

  • A total mean absolute relative difference (MARD) of 8.7%
  • 93.8 percent% 20/20
  • 99% of the sensor readings were clinically accurate and safe for treatment decisions

Expected Features and Benefits of the Dexcom G7

  • 60% smaller carrying system than G6
  • Smaller all-in-one sensor applicator and transmitter
  • 30-minute warm-up phase
  • Compatibility with insulin delivery devices
  • Maintaining the great customer experience
  • Still best in class accuracy

“Initial clinical data has reinforced our belief that the Dexcom G7 builds on the high level of precision our G6-CGM has achieved,” said Jake Leach, executive vice president and chief technology officer, Dexcom. “The G7 is a completely redesigned CGM device; our users will get a whole host of new features that we believe will enhance the customer experience that has become synonymous with Dexcom.”

In addition to the MOBILE study and the G7 data, many other presentations and posters from ATTD underpinned the advantages of the CGM from Dexcom for intensive insulin management as well as use in inpatient facilities and during pregnancy.

Über DexCom, Inc.

Headquartered in San Diego, California, DexCom, Inc. is dedicated to helping people better manage their diabetes symptoms through the development and marketing of continuous glucose monitoring (CGM) products and tools for adult and pediatric patients. Thanks to the exceptional performance, patient comfort and lifestyle flexibility that are at the heart of DexCom technology, users have consistently rated DexCom the highest for customer satisfaction and loyalty. More information is available at www.dexcom.com.

The source language in which the original text is published is the official and authorized version. Translations will be included for a better understanding. Only the language version that was originally published is legally valid. You should therefore compare the translations with the original language version of the publication.

.

Naples, future Pompeii? A disaster announced!

“We do not know when, or with what energy, but we know for sure that the eruption will occur”, immediately launched the volcanologist Claudio Scarpati. There is first of all the one that we see, which sits majestically on the Bay of Naples and which has been talked about since the dawn of time with the destruction of the cities of Pompeii and Herculaneum: Vesuvius. But it’s not just ancient history. Its last eruption dates from 1944 and despite its apparent calm, scientists are wary of the man nicknamed “The exterminator”. But the danger would rather come from those that we do not see! On the other side of the bay are the Phlegraean fields, a set of 72 volcanoes which extend over an area of ​​100 km2 on land and under the sea. They are classified among the super volcanoes for their dangerousness. And as if that were not enough, the Neapolitans must also deal with the neighboring mountains of fire: Etna and Stromboli, in an almost permanent eruption. Not to mention the underwater monsters like the Marsili where volcanic activity is constantly boiling.

Thanks to spectacular aerial images and anticipation, this documentary, both historical and scientific, follows a team of international experts who scrutinize the depths of these various volcanoes to warn of a future tragedy and to try to protect the 3 million people. very attached to their fertile land who would only have 30 minutes to flee… A hot topic!

“Doc Shot – Bay of Naples, the wrath of the volcanoes”, May 27, 2021, 10:35 p.m., La Une.

.

Free Games and Deals This Weekend: NBA 2K21, Crash Bandicoot 4, FIFA 21 and More

During this weekend, that is from Friday 14 to Sunday 16 May, a series of promotions are available thanks to which we can play for free or at a very reduced price on any platform, both in PS5, Xbox Series X/S, PS4, Xbox One, Nintendo Switch y PC as in cloud gaming services such as Stadia. Below we have selected some of the most outstanding so that you do not miss any of them:

Dos pruebas gratuitas en Free Play Days de Xbox Live Gold

Like every weekend, Xbox One and Xbox Series X / S users subscribed to Xbox Live Gold can enjoy free access to two new games during the Free Play Days. This time they are NBA 2K21 Y TT Isle of Man: Ride on the Edge 2 titles available at zero cost until Sunday, May 16. To play for free, you only need an active membership to this service, which is also integrated into Xbox Game Pass Ultimate.

Free Play Days from May 14 to 16.

Usually the games included in the Xbox Live Gold Free Play Days can be bought at a reduced price during the weekend, although this time it is different: those who want to stay forever with NBA 2K21 can do so at their usual price, although those who want to purchase TT Isle of Man: Ride on the Edge 2 Yes they can get it with a 70% off for its standard edition.

Free games on Steam and Epic Games Store

Major PC video game digital retailers are also offering free games this week. Steam currently has two promotions: the one that allows try for free Museum of Other Realities, a dreamlike game for VR, and the one that allows you to obtain the curious graphic adventure for free forever The Dream Machine, whose graphics are made entirely of clay and cardboard. The first promotion will finish in 10 days while the second will finish in three days.

Screenshot of The Lion's Song, this week's free game on the Epic Games Store.

Epic Games Store, for its part, has also already updated its weekly promotion of free PC games: this time the platform is giving away The Lion’s Song, an emotional standalone graphic adventure divided into several chapters. This game is available for free, without the need for a paid subscription, until next Thursday, May 20 at 5:00 p.m. (Spanish peninsular time). Next week the platform will give away a game whose title has not yet been revealed.

May free games on PS Plus, Xbox Live Gold, Prime Gaming and Stadia

It should be remembered that the main subscription games services already have their free games available for May. On PS4 and PS5 You can now download the ones from PS Plus, for example, a selection made up mainly of Wreckfest, exclusively on the console next-gen, yes, and Battlefield V, available on both consoles. They can also be downloaded to both systems Stranded Deep Y Waves Out!, a Spanish indie developed under the umbrella of PS Talents. In addition and within the Play at Home promotion, you have the last hours all PS4 and PS5 users to free download Horizon: Zero Dawn, until tomorrow at 05:00 (Spanish peninsular time).

Xbox Live Gold It also offers its first free games of May now: they can now be downloaded on Xbox One and Xbox Series X / S Armello (available from May 1 to May 31) and LEGO Batman (available from May 1 to 15). This weekend, precisely, the other two tickets will be activated at zero cost this month, namely, Dungeons 3 (available from May 16 to June 15) and Tropico 4 (available from May 16 to 31).

On the other hand, Prime Gaming has added to its button new free games such as Yoku’s Island Express, Faraway: Director’s Cut, The Blind Prophet, A Blind Legend O Healer’s Quest, while Stadia Pro also offers new games to its subscribers, specifically two: Hundred Days: Winemaking Simulator Y Street Power Football.

Ofertas en PS4, Xbox One, Nintendo Switch y PC

In addition to all these free games, during this weekend you can find great discounts on PS4, Xbox One, Nintendo Switch and PC games, titles that, in the case of Sony and Microsoft consoles, can also be purchased on PS5 and Xbox Series X / S to enjoy them through the backward compatibility of both platforms. Below you can see the most outstanding offers of each of these systems:

PS4 Deals

Ofertas Xbox One

Ofertas Nintendo Switch

Ofertas Steam

  • Overcooked! All You Can Eat 31,99
  • Total War: Three Kingdoms 29,99
  • DOOM Eternal 19,79
  • Narita Boy 18,74
  • Sam & Max Save The World 13,43
  • Going Under 9,99
  • Blasphemous 9,99
  • Middle-earth: Shadow of Mordor7,99
  • Total War: Shogun 2 7,49
  • Terraria 4,99

.